3/21
09:46 am
tecx
Tectonic Therapeutic (NASDAQ: TECX) had its price target lowered by analysts at Wells Fargo & Company from $112.00 to $101.00. They now have an "overweight" rating on the stock.
Low
Report
Tectonic Therapeutic (NASDAQ: TECX) had its price target lowered by analysts at Wells Fargo & Company from $112.00 to $101.00. They now have an "overweight" rating on the stock.
3/20
04:01 pm
tecx
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Medium
Report
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
2/20
08:00 am
tecx
Tectonic Therapeutic to Participate in March Investor Conferences
Low
Report
Tectonic Therapeutic to Participate in March Investor Conferences
2/3
07:12 am
tecx
Tectonic Announces $185 Million Private Placement [Yahoo! Finance]
Medium
Report
Tectonic Announces $185 Million Private Placement [Yahoo! Finance]
2/3
06:30 am
tecx
Tectonic Announces $185 Million Private Placement
Medium
Report
Tectonic Announces $185 Million Private Placement
1/31
10:27 am
tecx
Tectonic Therapeutic (NASDAQ: TECX) had its price target raised by analysts at Wells Fargo & Company from $79.00 to $112.00. They now have an "overweight" rating on the stock.
High
Report
Tectonic Therapeutic (NASDAQ: TECX) had its price target raised by analysts at Wells Fargo & Company from $79.00 to $112.00. They now have an "overweight" rating on the stock.
1/30
07:09 am
tecx
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF [Yahoo! Finance]
High
Report
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF [Yahoo! Finance]
1/30
06:30 am
tecx
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
High
Report
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF